Headlines
BioVersys launches IPO seeking to raise 80 million Swiss francs
Published by Global Banking & Finance Review®
Posted on January 29, 2025
1 min readLast updated: January 27, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on January 29, 2025
1 min readLast updated: January 27, 2026
BioVersys launches an IPO on the SIX stock exchange, aiming to raise up to 80 million Swiss francs. GSK commits 3.5 million francs to the offering.
ZURICH (Reuters) - Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.
The IPO implied a base offer size of around 75 million francs, rising to about 80 million francs ($88.53 million) if the over-allotment option is fully exercised, the firm said.
Book-building is expected to end on Feb. 5 and the final offer size should be published the next day, with the first day of trading earmarked for Feb. 7, it said.
The company, which focuses on research and development of antibacterial products, said last week about half of the stock would be subscribed by existing shareholders.
Among them, Britain's GSK has committed to investing 3.5 million francs in the IPO, BioVersys said.
($1 = 0.9036 Swiss francs)
(Writing by Dave Graham; Editing by Ludwig Burger)
The IPO is priced at 36 Swiss francs ($39.84) per share.
BioVersys aims to raise around 75 million francs, potentially increasing to about 80 million francs if the over-allotment option is fully exercised.
The first day of trading is earmarked for February 7.
Britain's GSK has committed to investing 3.5 million francs in the IPO.
BioVersys focuses on the research and development of antibacterial products.
Explore more articles in the Headlines category
